These are news releases that are related to our Investor efforts. Releases are listed in chronological order and are archived by year. Sign-up to receive news as it is released using the email and RSS tools below.
Jul 25, 2013Agenus to Host Conference Call Beginning at 11 a.m. ET Today
LEXINGTON, Mass.--(BUSINESS WIRE)--Agenus Inc. (Nasdaq:AGEN), a biotechnology company working to develop novel immunology based treatments for cancers and infectious diseases, today announced its...
Jul 22, 2013
Agenus Inc. (Nasdaq: AGEN), a developer of therapeutic vaccines for cancer and infectious diseases, today announced that the company will be presenting at the JMP Securities 8th Annual Healthcare...
Jul 18, 2013
Agenus Inc. (NASDAQ: AGEN) will release its second quarter 2013 financial results before the market opens on July 25, 2013. Agenus executives will host a conference call at 11:00 a.m. Eastern Time...
Jun 10, 2013
Agenus Inc. (NASDAQ: AGEN) invites investors and the general public to its Annual Shareholders’ Meeting at 5:00 p.m. ET on Wednesday, June 12, 2013. The meeting will be held at the company's...
May 22, 2013Agenus Announces Initiation of Enrollment in NCI-Sponsored Randomized Trial of Prophage G-200 Vaccine with Avastin in Treatment of Brain TumorsStudy seeking to enroll 222 patients; largest vaccine trial ever funded by NCI in brain tumors and the largest cancer vaccine study ever conducted in combination with Avastin
Agenus Inc. (NASDAQ: AGEN) today announced enrollment has started for a large, randomized Phase 2 study of Prophage G-200 (Heat Shock Protein Peptide Complex-96 or HSPPC-96) vaccine in combination...